Lestaurtinib

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C48402

A drug being studied in the treatment of acute leukemias and some other types of cancer. It binds to a protein that is present on the surface of some types of cancer cells and stops them from dividing. CEP-701 is a type of receptor tyrosine kinase inhibitor and a type of indolocarbazole alkaloid.

111358-88-4

C26H21N3O4

C48402

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

CTRP

GDC

FDA

An orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)

Lestaurtinib

DO989GC5D1

lestaurtinib

CEP-701

LESTAURTINIB

SPM-924

KT-5555

9,12-Epoxy-1H-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)-

Lestaurtinib

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C25855

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C28496

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

Lestaurtinib

Lestaurtinib

Lestaurtinib

367053

367053

367053

Lestaurtinib

Thesaurus:C48402

Lestaurtinib

Pharmacologic Substance

C1541677

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1967

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129825